CVS Jan 2021 27.500 put

OPR - OPR Delayed Price. Currency in USD
0.0000 (0.00%)
As of 1:41PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2800
Expire Date2021-01-15
Day's Range0.2800 - 0.2800
Contract RangeN/A
Open InterestN/A
  • American City Business Journals

    UPS' new 'drone airline' subsidiary flies forward with first big-name customers

    UPS said it's built on the company's industry-first, hospital network-focused drone delivery program by signing new customers.

  • PR Newswire

    CVS Health Corporation To Hold Third Quarter 2019 Conference Call

    WOONSOCKET, R.I., Oct. 23, 2019 /PRNewswire/ -- CVS Health Corporation (CVS) will hold a conference call with analysts and investors on Wednesday, November 6, 2019, at 8:00 a.m. (ET) to discuss its financial results for the third quarter of 2019. An audio webcast of the conference call will be broadcast simultaneously through the Investor Relations portion of the CVS Health website for all interested parties. CVS Health is the nation's premier health innovation company helping people on their path to better health.

  • PR Newswire

    Medicare Star Ratings show 3 out of 4 Aetna Medicare Advantage members enrolled in a 4.5 Star-rated plan or higher

    Commitment to quality leads to improved member health outcomes and helps Aetna earn its first 5-star plan and highest overall weighted average rating among national health insurers* HARTFORD, Conn. , Oct. ...

  • MarketWatch

    Michaels gives interim CEO the permanent job

    The Michaels Companies Inc. said Tuesday that it had tapped its interim chief executive to take on that role permanently. Mark Cosby had been serving in the interim chief executive position since February 2019 and had stints at Office Depot Inc. , CVS Health Corp.'s Caremark, and Macy's Inc. prior to joining the crafts retailer. "The search committee conducted an exhaustive evaluation of many outstanding candidates and unanimously concluded that Mark brings the right strategic vision and operating skill to lead Michaels into a new chapter," Chairman James Quella said in a release. Michaels shares were inactive in premarket trading. The stock has tumbled 27% so far this year, while the S&P 500 has gained 20%.

  • Walgreens Stock: What to Expect from Its Q4 Earnings
    Market Realist

    Walgreens Stock: What to Expect from Its Q4 Earnings

    Walgreens is scheduled to report its fourth-quarter earnings before the markets open on October 28. We expected a limited downside in Walgreens stock.

  • Reuters

    UPDATE 1-Drugstore drones: UPS will fly CVS prescriptions to U.S. customers

    United Parcel Service Inc's new Flight Forward drone unit will soon start home prescription delivery from CVS Health Corp. The service, which will debut in one or two U.S. cities in the coming weeks, shows how the parcel delivery company plans to expand its upstart drone business beyond hospital campuses. "Flight Forward will work with new customers in other industries to design additional solutions for a wide array of last-mile and urgent delivery challenges," UPS Chief Strategy and Transformation Officer Scott Price said.

  • CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know

    CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know

    CVS Health (CVS) closed the most recent trading day at $65.70, moving -0.7% from the previous trading session.

  • UPS has a new flight path — drone home delivery
    Yahoo Finance

    UPS has a new flight path — drone home delivery

    UPS announced the expansion of its Flight Forward drone delivery subsidiary which includes the University of Utah Health Network and CVS Pharmacies.

  • A Move to Managed Care Will Strengthen UnitedHealth Stock

    A Move to Managed Care Will Strengthen UnitedHealth Stock

    UnitedHealth (NYSE:UNH) stock jumped on earnings recently. But a bigger earnings catalyst came a few days later. UnitedHealth is getting into managed care.Source: Ken Wolter / Managed care has been the biggest healthcare story of the decade, the truest legacy of the Affordable Care Act. Under managed care companies focus on wellness rather than illness. They control costs by owning the places people go to for care and telling them what medicines they should take.Over the last 10 years Centene (NYSE:CNC) shares have risen almost 950% on Medicare and Medicaid contracts. UNH, which most consider the star of the healthcare sector, is up 840% in that time.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Sell Before December's Meltdown Now UnitedHealth's Optum unit has created an "accountable care" program in southern California. The sector will never be the same. Everyone in the PoolUnitedHealth had been doing great under the old model. It generated $5 billion in profit during the third quarter, and its health services business is now nearly half its revenue.You might ask, why change?Two reasons. First, because competitors are doing it. Second, because it can.CVS Health's (NYSE:CVS) acquisition of Aetna has made it the first true competitor to UNH, at least in terms of revenue. CVS plans to use its thousands of drug stores and hundreds of in-store clinics to deliver first-line care to millions of people.Walmart (NYSE:WMT) has opened a massive front-line clinic facility in Georgia. Amazon (NASDAQ:AMZN) is taking over 1 million people out of the market with its Haven healthcare unit, also a managed care system.UnitedHealth, meanwhile, has been laying its plans for nearly a decade. Optum has become a true competitor to companies like Cerner (NASDAQ:CERN) in electronic health records. UNH's acquisition of Catamaran means it has a pharmacy benefit manager comparable to that of Cigna's (NYSE:CI) Express Scripts unit. UnitedHealth has also been quietly buying up care providers like DaVita Medical Group, which provides kidney dialysis.Along the way there have been mistakes. Harken Health, which tried to compete with Kaiser Permanente, was closed. But the company's sheer size now gives it the ability to play hardball with even large hospitals.The new Optum offering, called the SignatureValue Harmony Network, will start with 1.5 million customers, combining Optum's own providers. With DaVita, OptumCare now has more physicians in its networks than HCA Healthcare (NYSE:HCA), the largest hospital operator. Why Managed Care WorksManaged care works because chronic conditions like diabetes, heart disease and kidney failure represent 75% of the national health bill -- and they account for even more of Medicare and Medicaid spending.These conditions can be prevented by lifestyle changes. Careful management can also keep people out of hospitals. Keeping people out of hospitals is the key to managing risks, as Centene has shown.UNH's moves put it in line with industry trends. Its size gives it the power to handle massive amounts of this business profitably. The Bottom Line on UnitedHealth StockProposals for reforming the nation's healthcare system are all geared toward the managed care model.UnitedHealth now has the infrastructure to deliver this model to the mass market.Given the company's size, a market cap more than double that of any insurance rival, revenue that has grown by more than one-third since 2015, this move is a very big deal.UnitedHealth stock is still cheap. Its trailing price-to-earnings ratio of 18 is in line with the market. While the dividend yields just 1.8%, it has nearly tripled in the last five years. UNH has one of Washington's largest lobbying budgets, and its political contributions are usually split evenly between the parties.UnitedHealth, in short, looks ready for nearly anything 2020 could throw at it.Dana Blankenhorn is a financial and technology journalist. He is the author of the environmental story, Bridget O'Flynn and the Bear, available at the Amazon Kindle store. Write him at or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in CVS and AMZN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell Before December's Meltdown * 7 Software Stocks to Buy for Growth * 3 Large-Cap Stocks to Buy After Earnings The post A Move to Managed Care Will Strengthen UnitedHealth Stock appeared first on InvestorPlace.

  • CVS Health steps up safe drug disposal strategy
    American City Business Journals

    CVS Health steps up safe drug disposal strategy

    CVS Health is doubling the number of in-store drug disposal kiosks in Massachusetts locations, as part of a broader effort to increase safe drug disposal options throughout the country.

  • CVS Health To Expand Safe Medication Disposal Program in Massachusetts, Giving Customers Drug Disposal Options in All CVS Pharmacy Locations
    PR Newswire

    CVS Health To Expand Safe Medication Disposal Program in Massachusetts, Giving Customers Drug Disposal Options in All CVS Pharmacy Locations

    BOSTON, Oct. 21, 2019 /PRNewswire/ -- In its continuing commitment to help build healthier communities, CVS Health (CVS) today announced the expansion of its safe medication disposal program, giving customers access to safer, easier and more convenient drug disposal options at every CVS Pharmacy location in Massachusetts at no cost.

  • CVS Stock: Is It A Buy Right Now? Here's What Earnings, Charts Show
    Investor's Business Daily

    CVS Stock: Is It A Buy Right Now? Here's What Earnings, Charts Show

    What’s the prognosis for CVS stock? Here is what the fundamentals and technical analysis say about buying CVS stock now.


    Philip Morris and 9 More Stock Picks Using Bernstein’s Quant-Aided Analysis

    Bernstein Research published its latest Quant+Fundamental stock picks. Three names are holdovers from April: Philip Morris, CVS Health, and Southwest Airlines.

  • Moody's

    Rite Aid Corporation -- Moody's says Rite Aid's proposed Tender Offer is a distressed exchange; PDR downgraded to Caa3-PD

    Moody's Investors Service ("Moody's") today stated that if the tender offer announced by Rite Aid Corporation on 15 October 2019 proceeds as outlined, it will constitute a distressed exchange, which is an event of default under Moody's definition of default. The Company announced that it recently completed a privately negotiated purchase from a noteholder and its affiliated funds of $84.1 million aggregate principal amount of its senior unsecured notes maturing 2027 and 2028 at 61% of par. The company also announced that it has commenced cash tender offers to purchase up to $100 million aggregate principal amount of its senior unsecured notes due 2027 and 2028.

  • PR Newswire

    Aetna Announces the 2019 Voices of Health Competition Winners

    HARTFORD, Conn. , Oct. 18, 2019 /PRNewswire/ -- Aetna, a CVS Health (NYSE: CVS) company, today announced the winners of the 2019 Voices of Health competition, a celebration of grassroots non-profit organizations ...

  • MarketWatch

    Sanofi recalls Zantac because of possible contamination with potentially cancer-causing NDMA

    Sanofi announced Friday a recall of over-the-counter heartburn medication Zantac in the U.S. and Canada, because of possible contamination with N-nitrosodimethylamine (NDMA), which is believed to cause cancer. The U.S.-listed stock fell 0.9% in morning trading. Sanofi said it was working with health authorities to determine the level and extent of the recall. The recall comes less nearly three weeks after CVS Health Corp. , Walgreens Boots Alliance Inc. and Rite Aid Corp. said they were pulling Zantac from their drugstores' shelves following a Food and Drug Administration warning that the the product could contain low levels of NDMA. "Evaluations are ongoing on both drug substance (active ingredient) and finished drug product," Sanofi said Friday in a statement. "Due to inconsistencies in preliminary test results of the active ingredient used in the U.S. and Canadian products, Sanofi has made the decision to conduct the voluntary recall in the U.S. and Canada as the investigation continues." Sanofi's shares have gained 6.2% year to date, while the SPDR S&P Pharmaceuticals ETF has gained 2.0% and the S&P 500 has climbed 19.5%

  • CVS Health Corporation (NYSE:CVS) Is About To Go Ex-Dividend, And It Pays A 0.8% Yield
    Simply Wall St.

    CVS Health Corporation (NYSE:CVS) Is About To Go Ex-Dividend, And It Pays A 0.8% Yield

    CVS Health Corporation (NYSE:CVS) stock is about to trade ex-dividend in 4 days time. This means that investors who...

  • PR Newswire

    CVS Health Announces $2.5 Million in New Funding to Help Build Healthier Communities in Ohio

    WOONSOCKET, R.I., Oct. 16, 2019 /PRNewswire/ -- As part of its commitment to building healthier communities, CVS Health (CVS) today announced it and its private charity will be donating more than $2.5 million in Ohio over the next three years to improve the health and wellness of Ohioans across the state. The new funding from CVS Health and the CVS Health Foundation will help support Ohio nonprofits as they tackle critical health issues that the state is currently facing. Grants to a number of different organizations will focus on mitigating prescription opioid abuse and misuse, expanding access to health care for underinsured and uninsured populations, and helping people to quit smoking.


    CVS Stock Is Rising as Its Integration Gives It a ‘Competitive Advantage’

    “We believe the company is one of the best positioned companies across our coverage universe over the longer term,” J.P. Morgan analyst Lisa Gill wrote.

  • Signs That Your Trading Will Ruin Your Retirement - October 15, 2019

    Signs That Your Trading Will Ruin Your Retirement - October 15, 2019

    Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

  • CVS Health (CVS) Gains As Market Dips: What You Should Know

    CVS Health (CVS) Gains As Market Dips: What You Should Know

    In the latest trading session, CVS Health (CVS) closed at $62.99, marking a +0.08% move from the previous day.

  • Legacy retailers scramble to offload Market Street space
    American City Business Journals

    Legacy retailers scramble to offload Market Street space

    Worsening street conditions and shifts in the retail industry have an increasing number of tenants interested in downsizing.

  • 10 Hot Stocks Staging Huge Reversals

    10 Hot Stocks Staging Huge Reversals

    Often times the best performing stocks in the stock market are "reversal" stocks, or beaten up stocks that have been down for a long time, and then suddenly turn on a dime and shoot higher. These reversal stocks can often rally 20%, 40%, or 60%-plus in a matter of months while the market moves up a few percentage points during that stretch.In other words, if you're looking for a big winner in a short period of time, look for reversal stocks.Finding these reversal stocks, however, can be hard, mostly because momentum is a very real thing in the market. Stocks that have been trending higher, usually continue to trend higher. Stocks that have been trending lower, usually continue to trend lower. According to research from Professor Hendrik Bessembinder of Arizona State University, the top 4% of listed companies have accounted for the entire net gain of the U.S. stock market since 1926 (in other words, winning stocks do all the winning).InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs such, finding stocks that go from trending lower, to breaking out higher, can be a tall order. * 7 Beverage Stocks to Buy Now But, you needn't worry about that. I've done the leg work for you, and have put together a list of 10 reversal stocks that have been staging huge reversals in 2019. Some of them will stay hot. Others won't. Let's take a deeper look, and find out of which of these reversals are worth buying, and which are worth skipping. Hot Stocks Staging Huge Reversals: CVS (CVS)Source: Shutterstock 5-Year Peak-to-Trough Drop: 55%Recent Rally (Duration): 20% (7 months)Shares of pharma retail giant CVS (NASDAQ:CVS) have been stuck in a secular decline over the past five years, dropping 55% from their mid-2015 highs to their early 2019 lows, as the company has run up against multiple operational headwinds, including legislation working to lower drug prices, a big opiod crisis, and competition from Amazon (NASDAQ:AMZN) and Walmart (NYSE:WMT), among a few other things.But, in early 2019, CVS stock got too cheap to ignore, with a decade-low forward earnings multiple of 8 and a decade-high dividend yield of essentially 4%. At the same time, pressure from Washington eased as proposed adverse changes for CVS failed to gain traction. CVS also started reporting better numbers -- the company has now reported five straight double-beat earnings reports -- amid a broad HealthHUB roll-out which provided differentiation from competitors.Against the backdrop of these various fundamental improvements, CVS stock has rattled off a 20% gain over the past seven months.Will the rally continue? Very likely, yes. The fundamental backdrop continues to improve. The numbers should remain solid. And, importantly, the stock is still dirt cheap, at almost 9-times forward earnings versus a five-year-average forward earnings multiple of 13. As such, CVS stock still has all the firepower necessary to stay in rally mode. GameStop (GME)Source: Shutterstock 5-Year Peak-to-Trough Drop: 94%Recent Rally (Duration): 67% (2 months)Five years ago, physical video game retailer GameStop (NYSE:GME) was considered just another a fairly strong retailer that had a choke-hold on the secular growth video game industry. Since then, everything has changed. Above all else, the video game industry has shifted from physical to digital. So, instead of buying games at their local GameStop, gamers can now just download games at home through the cloud. This has led to secular erosion in GameStop's core video game business, which has resulted in a 94% wipe-out in GME stock.But, this secular decline has sharply reversed course over the past two months. Since August 2019, GME stock has rattled off a near 70% gain thanks to a few things. First, "The Big Short" guy -- hedge fund manager Michael Burry, famously played by Christian Bale in "The Big Short" movie -- threw his hat into the ring, and said his fund owned a sizable stake in GameStop. Second, it became widely known that next year's next-gen video game consoles will still have physical disk drives. Third, investors started to get really excited about next year's video game console upgrade cycle: just look at the stocks of Activision (NASDAQ:ATVI), Electronic Arts (NASDAQ:EA), and Take-Two (NASDAQ:TTWO) over the past few months. * 10 Tech Stocks to Buy Now for 2025 Will GME stock stay hot? I think so. The valuation is still attractive -- $450 million market cap, with an estimated $480 million in cash sitting on the balance sheet -- and the numbers should improve meaningfully in 2020, as the first next-gen console upgrade cycle in seven years creates a rising tide across the entire video game industry. Investors will likely continue to buy ahead of that big catalyst, so long as the valuation remains ostensibly attractive, so GME stock will likely continue to rebound for the foreseeable future. Facebook (FB)Source: Ink Drop / 5-Year Peak-to-Trough Drop: 45%Recent Rally (Duration): 50% (10 months)Social media giant Facebook (NASDAQ:FB) was hit hard in 2018 by the Cambridge Analytica scandal, which turned into a global hot topic regarding how the company uses data to make billions of dollars in ad revenue. As the company's business model and practices were put under the microscope last year, FB stock got slaughtered on concerns that this close look would result in legal or consumer action that would ultimately cause Facebook's secular growth narrative to dry up. FB stock dropped 45% at the time.Fast forward to late 2019. None of that happened. Governments across the world and mainstream media took a very close look, and that's about all that actually happened. Consumers didn't leave the platform. Advertisers didn't pull money. Legislation didn't get enacted which materially restricted the company. Facebook maintained its 20%-plus revenue growth trajectory, all of its users, and most of its profits. In response, FB stock has rebounded 50% over the past 10 months.Will FB stock stay hot? Yes. If 2018 proved anything, it's that Facebook's digital properties are sticky -- consumers don't just use them and like them, they need them and can't go without them. Thus, usage and ad revenue growth for the foreseeable future will remain robust. That means Facebook will remain a 20%-plus revenue and profit grower for a long time. At just 19-times forward earnings, FB stock is very attractively valued considering the company's robust growth profile. Stage Stores (SSI)Source: WhisperToMe via Wikimedia Commons5-Year Peak-to-Trough Drop: 98%Recent Rally (Duration): 280% (2 months)The stock which has staged the biggest reversal on this list is department store operator Stage Stores (NYSE:SSI). For the past five years, Stage Stores has been thrown into the bucket of "retailers going extinct thanks to Amazon," as the company was a largely undifferentiated retailer in a hyper-competitive retail industry that had become over-crowded and was due for some consolidation. Comps, margins, and profits were all wiped out. SSI stock dropped a whopping 98%.Then, a turnaround strategy emerged in 2019. There are two businesses under the Stage Stores umbrella -- the full-price Stage Stores department stores, and the off-price Gordman's department stores. The full-price stores are struggling. The off-price stores are doing much better. Management's plan? Close a bunch of full-price stores, and convert the rest to off-price stores. In this sense, management is trying to turn Stage Stores into a mini TJX (NYSE:TJX) or Ross Stores (NASDAQ:ROST). Investors have bought into the turnaround hype. Shares are up an insane 280% over the past two months. * 7 of the Best Stocks to Buy for Growth Investors Can SSI stock stay in rally mode? Tough to say. If the off-price pivot works, then yes. SSI stock is really cheap relative to TJX or ROST stock. But, if the off-price pivot doesn't work, this huge 280% rally over the past two months could be just a head-fake. As such, at this point, SSI stock remains a high-risk, high-reward situation, and I don't have sufficient clarity to say that the risks outweigh the rewards, or vice versa. The stock truly feels like a wild-card here. (JD)Source: testing / 5-Year Peak-to-Trough Drop: 62%Recent Rally (Duration): 53% (11 months)Chinese e-retailer (NASDAQ:JD) was hit hard in 2018 amid a broad and rapid slowdown in China's economy, which resulted in JD's growth rates slowing dramatically at the same time that the company was investing big into improving and expanding operations (so margins were taking a hit, too). In response to slowing growth and declining margins, investors sold JD stock in droves. Shares dropped more than 60% from their peak in early 2018, to their trough in late 2018.But, over the past 11 months, JD stock has rattled off a 53% gain as the tide has turned. Specifically, China's economy has shown signs of life recently, particularly on the consumer and digital fronts (which are what matters most to JD). As China's economy has come back to life, JD's revenue growth rates have stabilized and even improved some. At the same time, 2018's big investments haven't continued in 2019, so margins have taken a big leg up this year, too.Can JD stock stay strong? I think so. China's digital and consumer economies have long runways for growth, and JD is becoming a bigger and more important player in those economies. Improving trade relations between the U.S. and China will also help things. JD's margins also seem positioned to keep marching higher. Thus, at this point in time, JD projects as a big revenue grower with strong upside margin drivers -- and that growth profile should ultimately keep JD stock on a long term march higher. Snap (SNAP)Source: dennizn / 5-Year Peak-to-Trough Drop: 82%Recent Rally (Duration): 200% (10 months)Social media company Snap (NYSE:SNAP) went public in early 2017 to a bunch of fanfare, and the stock spiked to $27 in just a few days. That fanfare died quickly, though, as the company's user growth flattened out and turned negative, while the revenue growth narrative lost momentum and the company's losses widened. From its post-IPO peak to late 2018, SNAP stock shed more 80% of its value.Then, everything changed. It all started with an Android app revamp and a cool face swap filter, which re-ignited user growth. Re-ignited user growth led to advertisers putting more money into the app, which led to recharged revenue growth. Recharged revenue growth led to more scale, which allowed the company to leverage opex and dramatically improve the margin profile. Snap turned into a user-growth, big revenue-growth, and strong margin-expansion company in 2019, which has led to SNAP stock essentially tripling over the past 10 months.Unfortunately, I'm not convinced that this big rally in SNAP stock can go on much longer. User growth trends are healthy, but relatively muted, and it increasingly appears that Snap will end up as a niche, direct photo-sharing app with no more than 300 million users. It also appears that the demographic will overwhelmingly remain the 16-to-24-year-old crowd, implying that the amount of ad dollars the platform can attract will be limited. Margins are improving, sure, but a lot of that improvement is because of huge stock comp -- and if you exclude that comp, the margin story becomes much more bleak. * 7 of the Worst IPO Stocks in 2019 All things considered, the big rally in SNAP stock in 2019 seems slightly overdone. The stock will likely go higher, but at a much less robust rate than it has over the past 10 months. Bed Bath & Beyond (BBBY)Source: Shutterstock 5-Year Peak-to-Trough Drop: 90%Recent Rally (Duration): 70% (2 months)Much like Stage Stores, general merchandise retailer Bed Bath & Beyond (NASDAQ:BBBY) has been thrown into the bucket of "retailers going extinct thanks to Amazon" over the past five years. That's because Bed Bath & Beyond is a largely undifferentiated physical retailer of products which Amazon, Walmart, and others are increasingly selling. Bed Bath & Beyond's comps, margins, and profits have all gone in the wrong direction -- and as they have, BBBY stock took a 90% tumble.Over the past two months, however, BBBY stock has staged a huge 70% rally from its multi-year lows thanks to three things. First, the stock just got way too cheap for its own good. Second, there was a huge momentum-to-value shift that provided a lift to beaten up stocks like BBBY. Third, the company found a new CEO -- and a winning pick, at that -- with the former merchandise head at Target (NYSE:TGT).Can BBBY stock keep moving higher? I think the best of the rally has already played out, but yes, the stock can grind higher from here. The fundamentals look largely maxed out, but the optics here are strong enough with the new CEO hire that you could see this stock shoot up and above the fundamentals in the near-term. Crocs (CROX)Source: Wannee_photographer / 5-Year Peak-to-Trough Drop: 45%Recent Rally (Duration): 71% (4 months)Casual footwear brand Crocs (NYSE:CROX) has been on fire over the past five years. Long story short, the company reduced its SKU count, focused its efforts and resources on the signature clog, and turned that signature clog into a winner in the "ugly shoe" trend. This has produced renewed revenue and profit growth at Crocs, which has powered a huge gain in CROX stock over the past five years. But, that multi-year rally hit a snag in early 2019 after a bad Q1 print -- and CROX stock dropped almost 50% after that print caused investors to think that the Crocs rebound was over.It wasn't. Second quarter numbers were much better, and the brand has only gained momentum over the past few months. In response, CROX stock has staged a huge rebound, soaring more than 70% over the past four months.How high can CROX stock go? Not much higher. I've been a big bull on CROX stock for a long time. But, above $30, the stock seems fully valued. This is a mid-to-high single-digit revenue grower with solid upside margin drivers. That growth profile creates runway to $2.50 in EPS by fiscal 2025. Based on a consumer discretionary average 20-times forward earnings multiple and 10% discount rate, that means CROX stock is fairly valued at $31 by the end of 2019. We are already there today. Target (TGT)Source: Robert Gregory Griffeth / 5-Year Peak-to-Trough Drop: 33%Recent Rally (Duration): 83% (10 months)Shares of general merchandise retail giant Target struggled over the past five years, dropping 33% from peak-to-trough at one point, as the company fell behind Walmart and Amazon in terms of next-gen commerce investments, and was increasingly at-risk of being left in the dust.That didn't happen. Instead, while Walmart and Amazon did get a head start on the next-gen commerce front, Target has come roaring back over the past two years. They've built out a big digital business which is now the fastest-growing online retail platform in the group. They've also created a robust omni-channel retail presence that is second-to-none, have doubled down on exclusive brand launches, and have expanded their product portfolio to offer more all-in-one convenience. In doing all these things, Target has increased its competitive positioning in the retail market. Comps, traffic, and profit numbers have all materially improved, and TGT stock has rattled off an 80%-plus gain to all-time-highs over the past 10 months. * 10 Best Cloud Growth Stocks Right Now What's next for TGT stock? In the near-term, some choppiness. The stock seems fully valued up here at $110. But, in the medium to long term, more upside. This company has figured out the next-gen commerce trend, meaning that the numbers here will remain rock solid for a lot longer. Those rock solid numbers should continue to push TGT stock higher. Micron (MU)Source: Charles Knowles / 5-Year Peak-to-Trough Drop: 55%Recent Rally (Duration): 54% (10 months)The multi-year bull market in memory chip giant Micron (NASDAQ:MU) came screeching to a halt in 2018, as MU stock lost more than half of its value amid a slowdown in demand in the global memory market, a rise in supply levels, and a broad decline in Micron's revenues, margins, and profits.MU stock has bounced back in 2019, rising more than 50% over the past 10 months, as the core supply/demand fundamentals in the memory market have shown signs of improving. That is, demand is slowly ramping back up, while inventory levels are gradually dropping off record highs. Thus, it appears that the worst of Micron's revenue and profit decline is over, and investors have consequently bought the dip in MU stock.Will this dip buying dynamic persist? I think so. Trade tensions are easing, and if they continue to ease, business confidence levels will rebound. That means capex levels will rebound, and a lot of capex these days goes into the semi market. Thus, the semi market should see a demand boost over the next few quarters. That demand boost will help Micron's revenues, margins, and profits move higher -- which should ultimately power MU stock higher.As of this writing, Luke Lango was long CVS, AMZN, GME, ATVI, EA, FB, JD, and MU. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Beverage Stocks to Buy Now * 10 Groundbreaking Technologies Created by Universities * 5 Semiconductor Stocks Worth Your Time The post 10 Hot Stocks Staging Huge Reversals appeared first on InvestorPlace.


    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CVS Health Corporation and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / October 14, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who acquired shares of CVS in exchange for their shares of Aetna Inc. in connection with CVS's acquisition of Aetna on November 28, 2018, are encouraged to contact the firm before October 14, 2019.

  • What to expect from the landmark opioid trial
    Yahoo Finance Video

    What to expect from the landmark opioid trial

    Four drug companies have reached a settlement for their role in the opioid crisis right before the landmark trial is set to begin. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Andy Serwer break down the details.